310 related articles for article (PubMed ID: 22494588)
1. Fluorodeoxyglucose positron emission tomography response and normal tissue regeneration after stereotactic body radiotherapy to liver metastases.
Stinauer MA; Diot Q; Westerly DC; Schefter TE; Kavanagh BD
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e613-8. PubMed ID: 22494588
[TBL] [Abstract][Full Text] [Related]
2. 18F-FDG PET and combined 18F-FDG-contrast CT parameters as predictors of tumor control for hepatocellular carcinoma after stereotactic ablative radiotherapy.
Huang WY; Kao CH; Huang WS; Chen CM; Chang LP; Lee MS; Chao HL; Chiu CH; Lo CH; Jen YM
J Nucl Med; 2013 Oct; 54(10):1710-6. PubMed ID: 23970365
[TBL] [Abstract][Full Text] [Related]
3. Stereotactic body radiotherapy (SBRT) for non-small cell lung cancer (NSCLC): is FDG-PET a predictor of outcome?
Clarke K; Taremi M; Dahele M; Freeman M; Fung S; Franks K; Bezjak A; Brade A; Cho J; Hope A; Sun A
Radiother Oncol; 2012 Jul; 104(1):62-6. PubMed ID: 22682749
[TBL] [Abstract][Full Text] [Related]
4. Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy.
Burdick MJ; Stephans KL; Reddy CA; Djemil T; Srinivas SM; Videtic GM
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1033-9. PubMed ID: 20472359
[TBL] [Abstract][Full Text] [Related]
5. Stereotactic body radiation therapy for liver oligometastases: predictive factors of local response by
Mazzola R; Fersino S; Alongi P; Di Paola G; Gregucci F; Aiello D; Tebano U; Pasetto S; Ruggieri R; Salgarello M; Alongi F
Br J Radiol; 2018 Jul; 91(1088):20180058. PubMed ID: 29750538
[TBL] [Abstract][Full Text] [Related]
6. A pilot trial of serial 18F-fluorodeoxyglucose positron emission tomography in patients with medically inoperable stage I non-small-cell lung cancer treated with hypofractionated stereotactic body radiotherapy.
Henderson MA; Hoopes DJ; Fletcher JW; Lin PF; Tann M; Yiannoutsos CT; Williams MD; Fakiris AJ; McGarry RC; Timmerman RD
Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):789-95. PubMed ID: 19473777
[TBL] [Abstract][Full Text] [Related]
7. Quantitative dosimetry for yttrium-90 radionuclide therapy: tumor dose predicts fluorodeoxyglucose positron emission tomography response in hepatic metastatic melanoma.
Eaton BR; Kim HS; Schreibmann E; Schuster DM; Galt JR; Barron B; Kim S; Liu Y; Landry J; Fox T
J Vasc Interv Radiol; 2014 Feb; 25(2):288-95. PubMed ID: 24269792
[TBL] [Abstract][Full Text] [Related]
8. Differentiation of tumor recurrence from radiation-induced pulmonary fibrosis after stereotactic ablative radiotherapy for lung cancer: characterization of 18F-FDG PET/CT findings.
Nakajima N; Sugawara Y; Kataoka M; Hamamoto Y; Ochi T; Sakai S; Takahashi T; Kajihara M; Teramoto N; Yamashita M; Mochizuki T
Ann Nucl Med; 2013 Apr; 27(3):261-70. PubMed ID: 23299492
[TBL] [Abstract][Full Text] [Related]
9. Residual ¹⁸F-FDG-PET uptake 12 weeks after stereotactic ablative radiotherapy for stage I non-small-cell lung cancer predicts local control.
Bollineni VR; Widder J; Pruim J; Langendijk JA; Wiegman EM
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e551-5. PubMed ID: 22417800
[TBL] [Abstract][Full Text] [Related]
10. 18F-FDG PET/CT predicts survival after radioembolization of hepatic metastases from breast cancer.
Haug AR; Tiega Donfack BP; Trumm C; Zech CJ; Michl M; Laubender RP; Uebleis C; Bartenstein P; Heinemann V; Hacker M
J Nucl Med; 2012 Mar; 53(3):371-7. PubMed ID: 22331219
[TBL] [Abstract][Full Text] [Related]
11. Serial assessment of FDG-PET FDG uptake and functional volume during radiotherapy (RT) in patients with non-small cell lung cancer (NSCLC).
Edet-Sanson A; Dubray B; Doyeux K; Back A; Hapdey S; Modzelewski R; Bohn P; Gardin I; Vera P
Radiother Oncol; 2012 Feb; 102(2):251-7. PubMed ID: 21885145
[TBL] [Abstract][Full Text] [Related]
12. CyberKnife radiosurgery for inoperable stage IA non-small cell lung cancer: 18F-fluorodeoxyglucose positron emission tomography/computed tomography serial tumor response assessment.
Vahdat S; Oermann EK; Collins SP; Yu X; Abedalthagafi M; Debrito P; Suy S; Yousefi S; Gutierrez CJ; Chang T; Banovac F; Anderson ED; Esposito G; Collins BT
J Hematol Oncol; 2010 Feb; 3():6. PubMed ID: 20132557
[TBL] [Abstract][Full Text] [Related]
13. (18)F-fluorodeoxyglucose positron emission tomography/computed tomography and magnetic resonance imaging in patients with liver metastases from uveal melanoma: results from a pilot study.
Orcurto V; Denys A; Voelter V; Schalenbourg A; Schnyder P; Zografos L; Leyvraz S; Delaloye AB; Prior JO
Melanoma Res; 2012 Feb; 22(1):63-9. PubMed ID: 22027909
[TBL] [Abstract][Full Text] [Related]
14. Microscopic and macroscopic tumor and parenchymal effects of liver stereotactic body radiotherapy.
Olsen CC; Welsh J; Kavanagh BD; Franklin W; McCarter M; Cardenes HR; Gaspar LE; Schefter TE
Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1414-24. PubMed ID: 18990508
[TBL] [Abstract][Full Text] [Related]
15. FDG-PET and stereotactic body radiotherapy (SBRT) for stage I non-small-cell lung cancer.
Hoopes DJ; Tann M; Fletcher JW; Forquer JA; Lin PF; Lo SS; Timmerman RD; McGarry RC
Lung Cancer; 2007 May; 56(2):229-34. PubMed ID: 17353064
[TBL] [Abstract][Full Text] [Related]
16. Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value.
Satoh Y; Onishi H; Nambu A; Araki T
Radiology; 2014 Jan; 270(1):275-81. PubMed ID: 24029640
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of 18f-fluorodeoxyglucose positron emission tomography-computed tomography in predicting survival in patients with unresectable metastatic melanoma to the liver undergoing yttrium-90 radioembolization.
Piduru SM; Schuster DM; Barron BJ; Dhanasekaran R; Lawson DH; Kim HS
J Vasc Interv Radiol; 2012 Jul; 23(7):943-8. PubMed ID: 22609292
[TBL] [Abstract][Full Text] [Related]
18. Evaluation for local failure by 18F-FDG PET/CT in comparison with CT findings after stereotactic body radiotherapy (SBRT) for localized non-small-cell lung cancer.
Takeda A; Kunieda E; Fujii H; Yokosuka N; Aoki Y; Oooka Y; Oku Y; Ohashi T; Sanuki N; Mizuno T; Ozawa Y
Lung Cancer; 2013 Mar; 79(3):248-53. PubMed ID: 23246123
[TBL] [Abstract][Full Text] [Related]
19. Using max standardized uptake value from positron emission tomography to assess tumor responses after lung stereotactic body radiotherapy for different prescriptions.
Ding M; Zollinger W; Ebeling R; Heard D; Posey R
J Appl Clin Med Phys; 2018 Nov; 19(6):226-233. PubMed ID: 30216639
[TBL] [Abstract][Full Text] [Related]
20. The role of positron emission tomography following radiosurgical treatment of malignant lung lesions.
Gill BS; Rivandi AH; Sandhu SP; Jensen LG; Nobiensky PD; Hoh CK; Sandhu AP
Nucl Med Commun; 2012 Jun; 33(6):607-12. PubMed ID: 22546820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]